Bicara Therapeutics Stock Forward View - Triple Exponential Smoothing
| BCAX Stock | 19.32 -0.08 -0.41% |
This reference page presents Triple Exponential Smoothing forecast data for Bicara Therapeutics Common. The model output shown here is derived from Bicara Therapeutics's historical price series and is provided for informational purposes.
The Triple Exponential Smoothing forecasted value of Bicara Therapeutics Common on the next trading day is expected to be 19.50 with a mean absolute deviation of 0.44 and the sum of the absolute errors of 26.08.As with simple exponential smoothing, in triple exponential smoothing models past Bicara Therapeutics observations are given exponentially smaller weights as the observations get older. In other words, recent observations are given relatively more weight in forecasting than the older Bicara Therapeutics Common observations. This Triple Exponential Smoothing forecast data for Bicara Therapeutics Common is sourced from the most recent available trading data and is intended solely as reference information. Triple Exponential Smoothing Price Forecast For the 18th of March 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Bicara Therapeutics Common on the next trading day is expected to be 19.50 with a mean absolute deviation of 0.44 , mean absolute percentage error of 0.35 , and the sum of the absolute errors of 26.08 .Please note that although there have been many attempts to predict Bicara Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Bicara Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Bicara Therapeutics | Bicara Therapeutics Price Prediction | Research Analysis |
Forecasted Value
Forecasting Bicara Therapeutics Common for the next session involves measuring the model's historical ability to define credible downside and upside scenarios. Used properly, these levels provide context around forecast dispersion rather than certainty about the next closing print.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Bicara Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Bicara Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0793 |
| MAD | Mean absolute deviation | 0.442 |
| MAPE | Mean absolute percentage error | 0.026 |
| SAE | Sum of the absolute errors | 26.0754 |
Other Forecasting Options for Bicara Therapeutics
For every potential investor in Bicara, whether a beginner or expert, Bicara Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better.Bicara Therapeutics Related Equities
The following equities are related to Bicara Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Bicara Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Bicara Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Bicara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bicara Therapeutics shares will generate the highest return on.
Bicara Therapeutics Risk Indicators
The analysis of Bicara Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Bicara Therapeutics' investment and either accepting that risk or mitigating it.
| Mean Deviation | 2.49 | |||
| Semi Deviation | 2.76 | |||
| Standard Deviation | 3.32 | |||
| Variance | 11.01 | |||
| Downside Variance | 7.89 | |||
| Semi Variance | 7.61 | |||
| Expected Short fall | -3.23 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Bicara Therapeutics
A coverage review of Bicara Therapeutics Common helps investors see when the security is attracting above-average attention from contributors and market observers. A disciplined read of coverage helps investors separate durable relevance from temporary noise.
Contributor Headline
Latest Perspective From Macroaxis
Bicara Therapeutics Short Properties
Short-interest signals around Bicara Therapeutics Common can help investors judge whether skeptical positioning is starting to pressure price predictability and market tone. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 54.4 M | |
| Cash And Short Term Investments | 489.7 M |